Topline safety and efficacy update of SUPLEXA-101, a First-in-Human, Single Agent Study of SUPLEXA Therapeutic Cells in 28 Patients with Metastatic Solid Tumors

Conclusions:

• Primary endpoint achieved with no drug related adverse events.
• Secondary endpoint achieved with the demonstration of a CR and a PR in 2 of 2 mCRC-MSI-H patients, each with a treatment history of prior chemo and prior ICI.
• SUPLEXA-101 Part B will explore a combination of SUPLEXA and ICI